Subsequently, we also illustrated that FDX1 was expressed differentially in different glioma molecular subtypes including LGG IDH mutant-1p/19q codel, LGG IDH mutant-1p/19q non-codel, LGG IDH mutant-wildtype and GBM IDH mutant, IDH-wildtype (p = 4.6e-05) (Figure 7D), suggesting a differential FDX1 expression in glioma molecular subtypes and indicating a potential function of FDX1 in prognosis and treatment of glioma. This evidence concerns the gene FDX1 and central nervous system cancer.